We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Editorial comment on "Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long‐term safety (TATE study)".
- Authors
Cabrera‐Perez, Javier S.; Eigenmann, Philippe; Akenroye, Ayobami
- Abstract
This article discusses the use of benralizumab, a biologic therapy, in children with severe eosinophilic asthma. The study aimed to obtain pharmacokinetic/pharmacodynamic (PK/PD) data on benralizumab in children aged 6 and above. The results showed promising reductions in asthma exacerbations and a significant decrease in peripheral eosinophils. However, there was a smaller improvement in lung function in the group receiving the approved adult dose, possibly due to differences between children and adults. The study suggests that extrapolation of trial findings from adults to children may be justifiable, but further research is needed.
- Subjects
EDITORIAL writing; ASTHMA; PHARMACOKINETICS; CHILD patients; ASTHMA in children; PULMONARY eosinophilia; WHEEZE
- Publication
Pediatric Allergy & Immunology, 2024, Vol 35, Issue 4, p1
- ISSN
0905-6157
- Publication type
Article
- DOI
10.1111/pai.14128